KR20200052770A - Composition for preventing or treating gastrointestinal disorders comprising extracts of Cassia tora - Google Patents
Composition for preventing or treating gastrointestinal disorders comprising extracts of Cassia tora Download PDFInfo
- Publication number
- KR20200052770A KR20200052770A KR1020180136178A KR20180136178A KR20200052770A KR 20200052770 A KR20200052770 A KR 20200052770A KR 1020180136178 A KR1020180136178 A KR 1020180136178A KR 20180136178 A KR20180136178 A KR 20180136178A KR 20200052770 A KR20200052770 A KR 20200052770A
- Authority
- KR
- South Korea
- Prior art keywords
- gastric
- extract
- gastritis
- composition
- ethanol
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 48
- 208000018522 Gastrointestinal disease Diseases 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 244000201986 Cassia tora Species 0.000 title description 9
- 235000014552 Cassia tora Nutrition 0.000 title description 9
- 208000007882 Gastritis Diseases 0.000 claims abstract description 32
- 235000013305 food Nutrition 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 208000007107 Stomach Ulcer Diseases 0.000 claims abstract description 13
- 201000005917 gastric ulcer Diseases 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 210000001156 gastric mucosa Anatomy 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 12
- 208000032843 Hemorrhage Diseases 0.000 claims description 9
- 230000000740 bleeding effect Effects 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 206010030113 Oedema Diseases 0.000 claims description 5
- 208000034158 bleeding Diseases 0.000 claims description 5
- 230000003628 erosive effect Effects 0.000 claims description 5
- 206010015150 Erythema Diseases 0.000 claims description 4
- 206010017815 Gastric perforation Diseases 0.000 claims description 4
- 208000023652 chronic gastritis Diseases 0.000 claims description 4
- 208000010643 digestive system disease Diseases 0.000 claims description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 3
- 206010017865 Gastritis erosive Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 59
- 230000002496 gastric effect Effects 0.000 abstract description 29
- 230000006378 damage Effects 0.000 abstract description 17
- 102000004190 Enzymes Human genes 0.000 abstract description 10
- 108090000790 Enzymes Proteins 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 10
- 208000000718 duodenal ulcer Diseases 0.000 abstract description 8
- 210000004211 gastric acid Anatomy 0.000 abstract description 7
- 210000002919 epithelial cell Anatomy 0.000 abstract description 6
- 230000004663 cell proliferation Effects 0.000 abstract description 4
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 4
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 4
- 230000004682 mucosal barrier function Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 16
- 239000003814 drug Substances 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000010171 animal model Methods 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 241000208340 Araliaceae Species 0.000 description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 description 8
- 235000008434 ginseng Nutrition 0.000 description 8
- 229940069428 antacid Drugs 0.000 description 7
- 239000003159 antacid agent Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000013641 positive control Substances 0.000 description 6
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 5
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 229960000381 omeprazole Drugs 0.000 description 5
- 229940126409 proton pump inhibitor Drugs 0.000 description 5
- 239000000612 proton pump inhibitor Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 230000009858 acid secretion Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000020710 ginseng extract Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000590002 Helicobacter pylori Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001458 anti-acid effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- -1 chryso-sbtusin Chemical compound 0.000 description 3
- 229960001380 cimetidine Drugs 0.000 description 3
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 230000027119 gastric acid secretion Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 239000011241 protective layer Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- RNXZPKOEJUFJON-UHFFFAOYSA-N aurantio-obtusin Chemical compound CC1=C(O)C(OC)=C2C(=O)C3=C(O)C(OC)=C(O)C=C3C(=O)C2=C1 RNXZPKOEJUFJON-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 229960001596 famotidine Drugs 0.000 description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229960000620 ranitidine Drugs 0.000 description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000277285 Cassia obtusifolia Species 0.000 description 1
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 1
- SBVZTBIAKFTNIJ-CZNQJBLBSA-N Cassiaside Chemical compound C1=CC=C2C=C3OC(C)=CC(=O)C3=C(O)C2=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SBVZTBIAKFTNIJ-CZNQJBLBSA-N 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- QBFJCZWBSLFTEE-UWBHIVAPSA-N Chryso-obtusin glucoside Chemical compound COC1=C2C(=O)C=3C(OC)=C(OC)C(OC)=CC=3C(=O)C2=CC(C)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QBFJCZWBSLFTEE-UWBHIVAPSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- QBFJCZWBSLFTEE-UHFFFAOYSA-N Glucochrysoobtusin Natural products COC1=C2C(=O)C=3C(OC)=C(OC)C(OC)=CC=3C(=O)C2=CC(C)=C1OC1OC(CO)C(O)C(O)C1O QBFJCZWBSLFTEE-UHFFFAOYSA-N 0.000 description 1
- JMDQOFZFOJHOMU-UHFFFAOYSA-N Glucoobtusifolin Chemical compound CC1=CC=2C(=O)C3=CC=CC(O)=C3C(=O)C=2C(OC)=C1OC1OC(CO)C(O)C(O)C1O JMDQOFZFOJHOMU-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027423 Metabolic alkalosis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- CFLNHFUPWNRWJA-UHFFFAOYSA-N Obtusin Chemical compound O=C1C2=CC(C)=C(O)C(OC)=C2C(=O)C2=C1C=C(OC)C(OC)=C2O CFLNHFUPWNRWJA-UHFFFAOYSA-N 0.000 description 1
- OBBJQZSMXOJMCN-UHFFFAOYSA-N Obtusin Natural products COc1cc2C=CC(=O)Oc2c3OCC(Oc13)C(=C)C OBBJQZSMXOJMCN-UHFFFAOYSA-N 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- SMTZFNFIKUPEJC-UHFFFAOYSA-N Roxane Chemical compound CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 SMTZFNFIKUPEJC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N Trimethylene glycol Natural products OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 1
- 229930182482 anthraquinone glycoside Natural products 0.000 description 1
- 150000008139 anthraquinone glycosides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- OXLQCHMJDJSJKF-UHFFFAOYSA-N cassiaside Natural products C1=C(O)C=C2C=C3OC(C)=CC(=O)C3=C(O)C2=C1OC1OC(CO)C(O)C(O)C1O OXLQCHMJDJSJKF-UHFFFAOYSA-N 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960003320 roxatidine Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000002731 stomach secretion inhibitor Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 결명자 추출물을 포함하는 위장질환 예방 및 치료용 조성물에 관한 것으로, 보다 구체적으로는 결명자 추출물을 유효성분으로 포함하는 위염, 위궤양 및 십이지장 궤양과 같은 위장질환의 예방 및 치료를 위한 약학적 조성물 및 식품 조성물에 관한 것이다. The present invention relates to a composition for the prevention and treatment of gastrointestinal diseases comprising the extract of ginseng, more specifically, a pharmaceutical composition for the prevention and treatment of gastrointestinal diseases such as gastritis, gastric ulcer and duodenal ulcer containing the extract of ginseng as an active ingredient And food compositions.
위는 식도를 통하여 들어온 음식물을 저장하고 소화되기 쉽게 잘게 부수며, 십이지장으로 음식물을 보내는 것을 조절하여 췌장효소의 분비와 조화를 이루어 효율적인 소화와 흡수가 되도록 하는 장기이다. 위는 음식물이 들어오면 이를 소화시키기 위해 강한 산인 위산을 분비하는데, 이때 위점막 보호층이 위산에 의해 위점막이 손상되지 않도록 작용한다. 위를 보호하는 위점막 보호층은 여러 종류의 인자로부터 공격을 받아 손상 받기 쉽다. The stomach is an organ that stores food that has entered through the esophagus and breaks it down easily for digestion, and regulates the transmission of food to the duodenum, so that it is in harmony with the secretion of pancreatic enzymes to enable efficient digestion and absorption. The stomach secretes a strong acid, gastric acid, to digest it when food comes in. At this time, the protective layer of the gastric mucosa acts to prevent the gastric mucosa from being damaged by the gastric acid. The gastric mucosa protective layer that protects the stomach is susceptible to damage from various types of factors.
위장질환의 원인은 다양하며, 이는 크게 위점막층의 손상을 야기하는 물리적 및 화학적 공격인자와 이들로부터 위점막 보호층을 방어하고 위 기능의 항상성을 유지하도록 작용하는 생체내 방어인자의 불균형에 기인한다. 대표적인 공격인자로는 스트레스, 알코올, 위산, 담배, 아스피린과 같은 진통소염제, 스테로이드 제제, 자극적인 음식, 영양결핍, 헬리코박터 파이로리의 감염 등이 있으며, 방어기전으로는 활성 산소종(reactive oxygen species, ROS)의 증가에 대한 항산화력의 약화, 위점막을 보호하는 점액, 프로스타글란딘(prostaglandin)의 생성 저하 및 조직 재생능력, 혈행 개선능력의 감소가 병인과 밀접하게 관련된다. 상기 요인으로 인해 위점막층이 손상되었을 때 미란, 발적, 출혈, 부종을 동반한 염증이 발생하게 되며, 손상이 심하여 위점막을 뚫고 점막 하단 및 근육층까지 손상이 확대된 경우 위궤양으로 발전하게 된다. 또한 상기 요인에 의해 십이지장 점막이 손상되어 가장 표면에 있는 점막층보다 깊이 패이면서 점막근층 이상으로 손상이 진행되면 십이지장 궤양이 발생한다.The causes of gastrointestinal diseases are various, and this is largely due to the imbalance of physical and chemical attack factors causing damage to the gastric mucosa layer and defense factors in vivo that act to protect the gastric mucosal protective layer from these and maintain homeostasis of gastric function. . Typical attack factors include stress, alcohol, stomach acid, cigarettes, analgesic anti-inflammatory drugs such as aspirin, steroid preparations, irritating food, malnutrition, and infection with Helicobacter pylori, and reactive oxygen species (ROS) as defense mechanisms. ), The weakening of the antioxidant power against the increase, the mucous membrane protecting the gastric mucosa, the decrease in the production of prostaglandin and tissue regeneration, and the ability to improve blood circulation are closely related to the etiology. When the gastric mucosal layer is damaged due to the above factors, inflammation accompanied by erosion, redness, bleeding, and edema occurs, and if the damage is severe and penetrates the gastric mucosa and the damage to the lower mucosa and muscle layer is enlarged, it develops into a gastric ulcer. In addition, when the duodenal mucosa is damaged by the above factors and is deeper than the mucosal layer on the surface, damage to the mucosal muscle layer or more occurs, and duodenal ulcer occurs.
따라서, 상기와 같은 공격인자에 의해 유발된 위염, 위궤양 및 십이지장궤양 등의 위장질환을 치료하기 위해서는 위산 분비 억제, 헬리코박터 파이롤리 균의 증식 억제, 점액 분비 촉진, 상피세포 재생 촉진, 항염증 등의 효능을 가진 약물이 필요하다.Therefore, in order to treat gastrointestinal diseases such as gastritis, gastric ulcer and duodenal ulcer caused by the above-mentioned attack factors, suppress gastric acid secretion, inhibit proliferation of Helicobacter pylori bacteria, promote mucus secretion, promote epithelial cell regeneration, anti-inflammatory, etc. Drugs with efficacy are needed.
현재 가장 대표적인 위장질환 치료제로는 과다한 위 분비액을 중화시키는 제산제(antacid), 위산 분비를 억제하는 히스타민 H2 수용체 길항제와 프로톤 펌프 저해제(proton pump inhibitor), 소화액에 대한 위 내막의 내성을 증가시키고 산 분비를 억제할 수 있는 프로스타글란딘(prostaglandin), 또는 위점막 보호제 등이 있다.Currently, the most representative gastrointestinal diseases are antacids that neutralize excess gastric secretion, histamine H2 receptor antagonists and proton pump inhibitors that inhibit gastric acid secretion, increase gastric lining resistance to digestive fluids, and acid secretion. And prostaglandin, or gastric mucosa protective agents.
상기 약물 중 제산제는 근본적인 치료가 아닌 일시적인 속효성을 위한 것으로, 위 내의 pH를 상승시켜 펩신의 활성을 저하함으로써 약효를 나타낸다. 그러나, 제산제를 사용할 시 무기물질 투여에 의해 변비, 설사, 대사성 알칼로시스(alkalosis), 요로결석증 등과 같은 부작용이 보고되어 있으며, 최근에는 제산제에 의한 산반동(acid rebound) 현상 등이 문제시되고 있다.Antacids in the drug are intended for temporary fast-acting rather than fundamental treatment, and exhibit drug efficacy by lowering the activity of pepsin by raising the pH in the stomach. However, when using an antacid, side effects such as constipation, diarrhea, metabolic alkalosis, urolithiasis, etc. have been reported by administration of inorganic substances, and recently, an acid rebound phenomenon caused by an antacid has been a problem.
또한, 상기 약물 중 가장 널리 사용되고 있는 히스타민 H2 수용체 길항제인 시메티딘(cimetidine)은, 위점막 내의 히스타민 수용체를 차단하여 히스타민 분자를 위세포가 차단함으로써 히스타민 분자가 위세포로 하여금 산의 분비 신호를 하지 못하도록 작용한다. 위궤양의 본격적 치료는 시메티딘이 1977년 발매되면서부터 시작되었으며, 여러 종류의 유도체가 개발되었다. 그 중 라니티딘(ranitidine), 파모티딘(famotidine), 록사티딘(roxatidine), 니자티딘(nizatidine) 등은 치료기간의 단축으로 임상에서 우수한 항궤양 효과를 나타내고 있으나, 약물투여 중지 후 재발률이 높은 단점이 있다. 또한, 시메티딘은 남성의 성욕감퇴, 남성의 여성형 유방, 호중구 감소증 등의 부작용을 비롯하여 약물상호작용까지 나타내므로 사용을 기피하는 현상을 보이고 있으며, 가장 최근의 약인 라니티딘이나 파모티딘은 장기간 사용 시 약효가 크게 감소되는 현상이 목격되고 있다. 또한, 프로톤 펌프 저해제로는 오메프라졸(omeprazole)과 란소프라졸(lansoprazole) 등이 있으며, 위벽세포에서의 산 분비를 최종단계에서 저해하여 강력한 산 분비억제 효과를 나타내는 것으로 알려져 있다. 그러나, 이들 약제에 의한 궤양치유 환자에게서도 재발률은 감소하지 않고 있으며, 연변, 설사, 발열, 두통, 피로감 등의 부작용이 보고되고 있다.In addition, cimetidine, the most widely used histamine H2 receptor antagonist among the drugs, blocks histamine receptors in the gastric mucosa so that gastric cells block histamine molecules so that histamine molecules do not cause gastric cells to signal acid secretion. Works. Full-scale treatment of gastric ulcers began when cimetidine was released in 1977, and several types of derivatives were developed. Among them, ranitidine, famotidine, roxatidine, and nizatidine have excellent anti-ulcer effects in the clinic due to a shorter treatment period, but the relapse rate after drug administration is stopped. There are high disadvantages. In addition, cimetidine shows side effects such as male libido, male-female breast, and neutropenia, as well as drug interactions, thus avoiding the use, and the most recent drugs, ranitidine and famotidine, are effective when used for a long time. The phenomenon is greatly reduced. In addition, proton pump inhibitors include omeprazole and lansoprazole, and are known to exhibit strong acid secretion inhibitory effects by inhibiting acid secretion in gastric wall cells at the final stage. However, even in patients with ulcerative healing caused by these drugs, the relapse rate has not decreased, and side effects such as feces, diarrhea, fever, headache, and fatigue have been reported.
상기와 같이, 히스타민 H2 수용체 길항제와 프로톤 펌프 저해제와 같은 항분비제의 개발로 지금까지 수술을 필요로 하는 위장질환을 약물 요법으로 치유할 수 있었다. 그러나, 치유된 위장질환의 대부분은 재발하거나, 재현되어 완전히 치유된 후에도 장기간에 걸친 유지 요법이 필요하며, 또한 유지 요법 중에도 재발 또는 재현하는 형상이 빈번히 관찰되고 있다. 따라서, 위산 분비를 억제할 목적으로 히스타민 H2 수용체 길항제와 프로톤 펌프 저해제만을 사용할 경우 위장질환의 치료에 있어 가장 중요한 재발율 억제효과를 기대할 수 없다.As described above, the development of anti-secretory agents such as histamine H2 receptor antagonists and proton pump inhibitors has been able to cure gastrointestinal diseases that require surgery so far with drug therapy. However, most of the cured gastrointestinal diseases are relapsed or reappeared, and a long-term maintenance therapy is required even after being completely cured, and a recurrence or reproducing shape is frequently observed during maintenance therapy. Therefore, when only the histamine H2 receptor antagonist and proton pump inhibitor are used for the purpose of suppressing gastric acid secretion, the most important recurrence inhibitory effect in the treatment of gastrointestinal diseases cannot be expected.
또한, 위점막 보호제의 경우 일반적으로 속효성이 적고 복용량이 많으며, 비교적 장기간 복용해야 하는 단점이 있으나, 재생점막이 정상과 유사하게 회복되는 것으로 알려져 있다. 따라서, 최근에는 제산제, 히스타민 H2 수용체 길항제 또는 프로톤 펌프 저해제와 같은 위산 억제제와 함께, 점막을 보호하고 조직수복을 촉진하며 점막혈류를 증가시키는 수크랄페이트(sucralfate), 비스무스 킬레이트(bismuth chelate)와 같은 위점막 보호제를 동시에 사용하고 있다.In addition, the gastric mucosa protective agent generally has a short-acting rate, a high dose, and disadvantages of having to be taken for a relatively long time, but it is known that the regenerated mucosa recovers similar to normal. Thus, recently, along with antacids, histamine H2 receptor antagonists or gastric acid inhibitors such as proton pump inhibitors, such as sucralfate, bismuth chelate, which protect the mucous membrane, promote tissue repair and increase mucosal blood flow. I am using gastric mucosa protective agent at the same time.
또한, 최근에는 헬리코박터 파이롤리 균을 제거할 목적으로 항생제가 사용되고 있다.In addition, antibiotics have recently been used to remove Helicobacter pylori bacteria.
위염, 위궤양 및 십이지장궤양 등의 위장질환의 주요 증상으로는 복통, 속쓰림, 더부룩함, 소화불량, 트림, 오심, 구토, 출혈 등이 있다. 상기 증상들을 완화시키기 위하여 속효성으로 제산제를 복용하거나 식사를 하는 경우가 있으나 이는 일시적일 뿐이고, 스테로이드성 및 비스테로이드성 소염진통제들은 부작용으로 인하여 사용이 제한되고 있다. 특히, 아스피린, 이부프로펜 등의 비스테로이드성 소염진통제들은 오히려 위궤양 또는 십이지장궤양을 심화시켜 궤양이 있는 환자에게는 사용을 극도로 자제하거나 제산제와 함께 복용시키는 등 사용에 많은 제한을 받고 있다. 따라서, 위장질환에서 나타나는 증상들을 완화하고, 오랜 시간 복용시에도 부작용이 적으면서 위를 보호할 수 있는 약물 개발의 필요성이 요구되고 있다.The main symptoms of gastrointestinal diseases such as gastritis, gastric ulcer and duodenal ulcer include abdominal pain, heartburn, bloating, indigestion, belching, nausea, vomiting, and bleeding. In order to alleviate the above symptoms, there are cases in which an antacid is taken or a meal is taken for a short time, but this is only temporary, and use of steroidal and nonsteroidal anti-inflammatory drugs is limited due to side effects. In particular, nonsteroidal anti-inflammatory drugs, such as aspirin and ibuprofen, are rather limited in their use, such as intensifying gastric ulcer or duodenal ulcer and refraining from using it or taking it with antacids. Therefore, there is a need to develop a drug capable of alleviating symptoms occurring in gastrointestinal disorders and protecting the stomach with fewer side effects even when taken for a long time.
따라서, 화학적 약물보다는 부작용이 적으면서 안정성이 확보된 생약재를 이용한 위장질환의 치료제에 관한 연구가 활발히 진행되고 있으며, 이에 본 발명자들은 결명자 추출물이 위장 보호에 효과가 있다는 사실을 발견함으로써 본 발명을 완성하였다. Therefore, studies on the treatment of gastrointestinal diseases using herbal medicines with less side effects and stability are secured rather than chemical drugs, and the present inventors have completed the present invention by discovering that the extract of the ginseng extract is effective in protecting the stomach. Did.
따라서, 본 발명에서 해결하고자 하는 기술적 과제는 안전하고 효과적인 위염 또는 위궤양 및 기타 관련 위장질환의 예방 또는 치료를 위한 조성물을 제공하는 것이다. Therefore, the technical problem to be solved in the present invention is to provide a composition for the prevention or treatment of gastritis or other related gastrointestinal diseases that are safe and effective.
상기한 기술적 과제를 해결하기 위하여, 본 발명에서는 결명자 추출물을 유효성분으로 포함하는 위장질환 예방 또는 치료를 위한 약학적 조성물을 제공한다.In order to solve the above technical problem, the present invention provides a pharmaceutical composition for the prevention or treatment of gastrointestinal diseases comprising the extract of the ginseng as an active ingredient.
또한, 본 발명에서는 결명자 추출물을 유효성분으로 포함하는 위장질환 예방 또는 개선을 위한 식품 조성물을 제공한다.In addition, the present invention provides a food composition for preventing or improving gastrointestinal diseases comprising the extract of gyeolmyeongja as an active ingredient.
본 명세서에서 용어 "위장질환"은 그 발생원인 및 기전과 무관하게 위점막의 손상을 동반하거나, 손상을 야기할 가능성이 있는 모든 질환 및 병태를 포함하는 광범위한 의미로 사용된다. 상기 위장관 질환은 급성위염, 만성 활동성 위염, 만성 위축성 위염과 같은 만성위염, 위궤양, 십이지장궤양, 위천공, 위출혈, 비스테로이드성 항염증약물과 연관된 소화 장애, 비궤양성 소화불량증, 위식도 역류 질환, 급성 상부 위장 출혈, 스트레스 궤양화, 헬리코박터 파일로리 감염, 및 상기 질환들로 인한 위점막의 미란, 출혈, 발적 및 부종과 같은 증상을 포함하나, 이에 제한되지 않는다. 바람직하게, 본 발명의 조성물에 의해 예방 또는 치료되는 대상 질환은 급성 위염, 만성 위염, 위궤양, 위천공, 및 상기 질환으로 인한 위점막의 미란, 출혈, 발적 및 부종을 포함한다.As used herein, the term "gastrointestinal disease" is used in a broad sense including all diseases and conditions that are accompanied by or are likely to cause damage to the gastric mucosa, regardless of its cause and mechanism. The gastrointestinal diseases include acute gastritis, chronic active gastritis, chronic gastritis such as chronic atrophic gastritis, gastric ulcer, duodenal ulcer, gastric perforation, gastric bleeding, digestive disorders associated with nonsteroidal anti-inflammatory drugs, non-ulcerative dyspepsia, gastroesophageal reflux disease , Acute upper gastrointestinal bleeding, stress ulceration, Helicobacter pylori infection, and symptoms such as erosion, bleeding, redness and edema of the gastric mucosa caused by these diseases. Preferably, target diseases to be prevented or treated by the compositions of the present invention include acute gastritis, chronic gastritis, gastric ulcer, gastric perforation, and erosion, bleeding, redness and edema of the gastric mucosa caused by the disease.
본 발명에서 사용되는 용어 "예방"은 질환 또는 질병을 보유하고 있다고 진단된 적은 없으나, 이러한 질환 또는 질병에 걸리기 쉬운 경향이 있는 개체에서 질환 또는 질병의 발생을 억제하는 것을 의미한다. The term "prevention" as used in the present invention has never been diagnosed as having a disease or a disease, but means to suppress the occurrence of a disease or disease in an individual who is prone to such disease or disease.
본 명세서에서 사용되는 용어 "치료"는 개체에서 (a) 질환 또는 질병의 발전의 억제 (b) 질환 또는 질병의 경감 및 (c) 질환 또는 질환의 제거를 의미한다. As used herein, the term “treatment” means (a) inhibition of the disease or development of the disease (b) alleviation of the disease or disease and (c) elimination of the disease or disease in an individual.
본 명세서에서 사용되는 용어 "개체"는 본 발명의 상기 조성물을 투여하여 증상이 호전될 수 있는 질환을 가진 인간을 포함한 원숭이, 소, 말, 돼지, 양, 개, 고양이, 랫드, 마우스, 침팬지 등의 포유동물을 의미한다.The term "individual" as used herein refers to monkeys, cows, horses, pigs, sheep, dogs, cats, rats, mice, chimpanzees, etc., including humans with diseases that may improve symptoms by administering the composition of the present invention. Means mammal.
본 발명의 유효성분으로 사용되는 결명자(Cassiae semen)는 콩과(Leguminosae)에 속하는 1년생 초본식물인 초결명(Cassia obtusifolia L.) 또는 긴강남차(Cassia tora L.)의 성숙한 종자로 북아메리카가 원산지이며, 성질은 약간 차고 맛은 달고 쓰며 짜고 독이 없다. 대한민국의 남쪽지방에서 재배되고 있는 결명자는 대부분 Cassia tora L.(CT)로 약재 및 차의 형태로 이용되어 왔다. 한방에서 청간명목(淸肝明目), 음허에 의하여 간양(肝陽)이 상승하는 것을 치료하고 간의 내풍(內風)을 평하게 하는 평간잠양(平肝潛陽) 및 장(腸)을 적셔주고 대변(大便)을 통하게 하는 윤장통변(潤腸通便) 등의 효능이 있다고 보고되었다(Hong, K. H., et al., (2012) Physicochemical properties of ethanol extracts and dietary fiber from Cassia tora L. seed. Korean J Food Nutr 25: 612-619) 및 (Professors of herbology in colleges of oriental medicine (2004) Herbology. Yeonglimsa, Seoul, Korea. 76-78, 549-550). 결명자의 주요 성분으로는 chrysophanol, physcion, emodin, aloe-emodin, obtusin, chryso-sbtusin 및 aurantio-obtusin 등과 같은 anthraquinone류와 glucoobtusifolin, glucochryso-obtusin 및 glucoaurantio-otusin 등과 같은 anthraquinone glycoside류 및 torachrysone, toralactone, rubrofusarin, cassiaside 등과 같은 naphthalene 유도체 등이 보고되었다(Seo, C. S., et al., (2014) Quantitative Analysis of Anthraquinones in Cassiae Semen by Processing Method. Kor J Pharmacogn 45 (3) : 200-208). Cassiae semen, used as an active ingredient of the present invention, is a mature seed of Cassia obtusifolia L., a first-year herbaceous plant belonging to the legumes (Leguminosae), or mature seed of Cassia tora L. Originating, slightly cold, tastes sweet, bitter, salty and non-toxic. Cassia tora L. (CT), which is mostly grown in the southern part of Korea, has been used as a medicine and tea. Treats the rise of liver yang due to cheonggan nom, umho in oriental medicine, and wets the liver with flat liver and flattening the liver to flatten the internal wind. It has been reported to have efficacy such as yuntongtongbyeon (주고 通 便) to give and pass feces (Hong, KH, et al., (2012) Physicochemical properties of ethanol extracts and dietary fiber from Cassia tora L. seed. Korean J Food Nutr 25: 612-619 ) and (Professors of herbology in colleges of oriental medicine (2004) Herbology . Yeonglimsa, Seoul, Korea. 76-78, 549-550). The main components of the terminus include anthraquinones such as chrysophanol, physcion, emodin, aloe-emodin, obtusin, chryso-sbtusin, and aurantio-obtusin, and anthraquinone glycosides, torach, and torals, such as glucoobtusifolin, glucochryso-obtusin and glucoaurantio-otusin, etc. , naphthalene derivatives such as cassiaside, etc. (Seo, CS, et al., (2014) Quantitative Analysis of Anthraquinones in Cassiae Semen by Processing Method.KOR J Pharmacogn 45 (3): 200-208).
본 발명에 있어서, "결명자 추출물"은 결명자를 통상의 방법에 의하여 추출한 추출물로서, 결명자로부터 추출한 추출액뿐만 아니라 이의 건조 분말 또는 이를 이용하여 제형화된 모든 형태를 포함한다.In the present invention, "terminator extract" is an extract extracted from terminator by a conventional method, and includes extracts extracted from terminator, as well as dry powder or all forms formulated using the extract.
상기 결명자 추출물은 물 또는 유기 용매를 사용하여 추출할 수 있는데, 추출한 액은 액체 형태로 사용하거나 또는 농축 및/또는 건조하여 사용할 수 있다. 상기 유기 용매는 메탄올, 에탄올, 이소프로판올, 부탄올, 에틸렌, 아세톤, 헥산, 에테르, 클로로포름, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, N,N-디메틸포름아미드(DMF), 디메틸설폭사이드(DMSO), 1,3-부틸렌글리콜, 프로필렌글리콜 또는 이들의 혼합용매이며, 추출물의 유효 성분이 파괴되지 않거나 최소화된 조건에서 실온 또는 가온하여 추출할 수 있다. The Cassia tora extract can be extracted using water or an organic solvent, and the extracted liquid can be used in liquid form or concentrated and / or dried. The organic solvent is methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1 , 3-butylene glycol, propylene glycol, or a mixed solvent thereof, and can be extracted at room temperature or by heating under conditions in which the active ingredient of the extract is not destroyed or minimized.
상기 추출 방법은 제한되지 않고, 예를 들어, 냉침추출, 초음파 추출, 환류 냉각 추출 등이 있다.The extraction method is not limited and includes, for example, cold needle extraction, ultrasonic extraction, reflux cooling extraction, and the like.
본 발명의 바람직한 실시양태에 따르면, 결명자 추출물은 결명자를 수세 및 건조한 다음 10배 부피의 물을 넣고 3시간 동안 3회 반복하여 환류 추출하였고, 필터에 거른 결명자 추출물을 동결건조한 후 물에 녹여 결명자 물 추출물을 수득할 수 있다.According to a preferred embodiment of the present invention, the ginseng extract is washed with water and dried the ginseng and then refluxed 3 times for 3 hours after adding 10 times the volume of water, and freeze-dried the ginseng extract filtered through the filter, dissolved in water, and dissolved in water. An extract can be obtained.
본 발명의 결명자 추출물은 추출, 분획, 또는 정제(분리, 분획)의 각 단계에서 얻어지는 모든 추출액, 분획, 정제물, 그들의 희석액, 농축액, 또는 건조물일 수 있다.Extract of the present invention can be all extracts, fractions, purified products, dilutions, concentrates, or dried products obtained at each stage of extraction, fractionation, or purification (separation, fractionation).
본 발명의 구체적인 실시양태에서, HCl/에탄올에 의한 유도 위염 동물에 결명자 추출물을 투여함으로써 위손상이 감소되었으며, 위산의 억제, 위의 점막 장병 보존, 세포 증식을 촉진하는 역할을 하는 PGE2 효소가 유의적으로 증가하였다.In a specific embodiment of the present invention, the gastrointestinal damage was reduced by administering the extract extract of HCl / ethanol-induced gastritis, and the PGE 2 enzyme, which serves to inhibit gastric acid, preserve gastric mucosal disease, and promote cell proliferation Significantly increased.
본 발명의 구체적인 실시양태에서, HCl/에탄올에 의한 유도 위염 동물에 결명자 추출물을 투여함으로써 위조직의 상피세포의 손상이 억제되어 보존되었다. In a specific embodiment of the present invention, the damage of epithelial cells of the gastric tissue was suppressed and preserved by administering the extract of the terminator to the gastritis induced by HCl / ethanol.
따라서, 본 발명의 결명자 추출물을 유효성분으로 포함하는 조성물은 위장질환 예방 또는 치료하기 위한 용도로 유용하게 사용할 수 있다.Therefore, the composition comprising the extract of the ginseng of the present invention as an active ingredient can be usefully used for the purpose of preventing or treating gastrointestinal diseases.
본 발명의 바람직한 구현예에서, 상기 결명자 추출물은 전체 조성물의 총 중량을 기준으로 0.001 내지 50 중량%, 바람직하게는 0.01 내지 30 중량%, 보다 바람직하게는 0.01 내지 10 중량%의 함량으로 포함될 수 있다.기준으로 하여 0.00001 내지 15.0 중량%, 보다 바람직하게는 0.0001 내지 10 중량%, 가장 바람직하게는 0.0001 내지 5 중량%의 양으로 포함될 수 있다. In a preferred embodiment of the present invention, the terminator extract may be included in an amount of 0.001 to 50% by weight, preferably 0.01 to 30% by weight, and more preferably 0.01 to 10% by weight based on the total weight of the total composition. It can be included in an amount of 0.00001 to 15.0% by weight, more preferably 0.0001 to 10% by weight, most preferably 0.0001 to 5% by weight, based on.
본 발명의 바람직한 구현예에 따르면, 결명자 추출물을 유효성분으로 포함하는 약학적 조성물을 제공한다.According to a preferred embodiment of the present invention, there is provided a pharmaceutical composition comprising the extract of terminator as an active ingredient.
본 발명의 약학적 조성물은 유효성분으로서 결명자 추출물 이외에 약학적으로 허용되는 담체를 포함한다. 본 발명의 약학적 조성물에 포함되는 약학적으로 허용되는 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. 적합한 약학적으로 허용되는 담체 및 제제는 Remington's Pharmaceutical Sciences (19th ed., 1995)에 상세히 기재되어 있다.The pharmaceutical composition of the present invention includes, as an active ingredient, a pharmaceutically acceptable carrier in addition to the extract of Cassia tora. The pharmaceutically acceptable carrier included in the pharmaceutical composition of the present invention is commonly used in formulation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, Calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, but is not limited thereto It does not work. The pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약학적 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 경구 또는 비경구 등의 다양한 경로로 투여할 수 있으며, 예컨대 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 주사에 의해 투여할 수 있다. 바람직하게는 비경구 투여 중 경피투여, 보다 바람직하게는 도포에 의한 국부 투여(topical application) 방식으로 적용된다.The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, and humans by various routes such as oral or parenteral, such as oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dura mater or cerebrovascular It can be administered by my injection. Preferably, it is applied by transdermal administration during parenteral administration, more preferably by topical application by application.
본 발명의 약학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. 본 발명의 약학적 조성물의 투여량은, 경구형 제형인 경우 성인 기준으로 0.001-100 ㎎/kg 의 양을 1일 1회 내지 수회 투여할 수 있으며, 외용제인 경우에는 성인 기준으로 1일당 1.0 내지 3.0 ml의 양으로 1일 1회 내지 5회 도포하여 1개월 이상 계속하는 것이 좋다. 다만, 상기 투여량은 본 발명의 범위를 한정하는 것은 아니다.Suitable dosages of the pharmaceutical compositions of the invention are variously prescribed by factors such as formulation method, mode of administration, patient's age, weight, sex, morbidity, food, time of administration, route of administration, rate of excretion, and response sensitivity. Can be. The dosage of the pharmaceutical composition of the present invention, in the case of an oral dosage form, the amount of 0.001-100 mg / kg per adult can be administered once to several times a day, and in the case of an external preparation, 1.0 to 1 per day based on the adult It is advisable to continue applying for 1 to 5 times a day in an amount of 3.0 ml for more than 1 month. However, the dosage does not limit the scope of the present invention.
본 발명의 약학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 산제, 과립제, 정제, 캅셀제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 연고, 크림 등의 외용제, 좌제 및 멸균 주사용액 등을 비롯하여 약학적 제제에 적합한 어떠한 형태로든 사용할 수 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention is prepared in a unit dose form by formulating using a pharmaceutically acceptable carrier and / or excipient according to a method that can be easily carried out by those skilled in the art to which the present invention pertains. Or it can be manufactured by incorporating into a multi-dose container. At this time, the formulation can be used in any form suitable for pharmaceutical formulations, including powdered, granular, tablet, capsule, suspension, emulsion, syrup, aerosol and other oral formulations, external preparations such as ointments, creams, suppositories, and sterile injectable solutions. , It may further include a dispersing agent or a stabilizer.
또한, 본 발명의 바람직한 구현예에 따르면, 결명자 추출물을 유효성분으로 포함하는 식품 조성물을 제공한다.In addition, according to a preferred embodiment of the present invention, it provides a food composition comprising the extract of gyeolmyeongja as an active ingredient.
본 발명의 식품 조성물은 유효성분으로서 결명자 추출물뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다.The food composition of the present invention, as an active ingredient, includes not only the extract of a terminator, but also a component that is commonly added in the manufacture of food, and includes, for example, protein, carbohydrate, fat, nutrient, seasoning and flavoring agent. Examples of the aforementioned carbohydrates include monosaccharides, such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides, etc .; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a flavoring agent, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizine, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.
예컨대, 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 본 발명의 결명자 추출물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다.For example, when the food composition of the present invention is prepared as a drink agent, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, worm extract, jujube extract, licorice extract, etc. have.
한편, 본 발명의 결명자 추출물은 식용하는 천연물질로서, 인체에 무해하다. 따라서, 본 발명의 결명자 추출물은 독성 및 부작용이 거의 없으므로 장기간 사용 시에도 안심하고 사용할 수 있으며, 특히 상기한 바와 같은 약학적 조성물 및 식품 조성물에 안전하게 적용할 수 있다.On the other hand, the extract of the ginseng of the present invention is an edible natural substance, which is harmless to the human body. Therefore, the extract of the ginseng of the present invention has little toxicity and side effects, and can be safely used even for long-term use. In particular, it can be safely applied to pharmaceutical and food compositions as described above.
이와 같이, 본 발명에 따른 결명자 추출물을 포함하는 조성물은 HCl/에탄올에 의한 유도 위염 동물에 투여함으로써 위손상이 감소되었으며, 위산의 억제, 위의 점막 장병 보존, 세포 증식을 촉진하는 역할을 하는 PGE2 효소가 유의적으로 증가할 수 있다. 또한, HCl/에탄올에 의한 유도 위염 동물에 결명자 추출물을 투여함으로써 위조직의 상피세포의 손상이 억제되어 보존되었다. 따라서, 본 발명의 결명자 추출물은 위염, 위궤양 및 십이지장 궤양과 같은 위장질환의 예방 및 치료를 위한 약학적 조성물 및 식품 조성물로 유용하게 사용될 수 있을 것으로 기대된다. As described above, the composition comprising the extract according to the present invention reduced gastric damage by administering to a gastrointestinal animal induced by HCl / ethanol, and inhibited gastric acid, preservation of gastric mucosal disease, and PGE, which promotes cell proliferation. 2 Enzymes can increase significantly. In addition, the damage of epithelial cells of the gastric tissue was suppressed and preserved by administering the extract of the terminator to the gastritis induced by HCl / ethanol. Therefore, it is expected that the extract of the ginseng of the present invention may be useful as a pharmaceutical composition and a food composition for the prevention and treatment of gastrointestinal diseases such as gastritis, gastric ulcer and duodenal ulcer.
도 1은 HCl/에탄올 투여 후, 위체부와 위저부의 점막 손상과 띠 모양으로 선상의 출혈을 관찰한 결과를 나타낸 것이다.
도 2는 HCl/에탄올 투여 후, 위염 동물모델에서 PGE2 효소 양을 측정한 결과를 나타낸 그래프이다.
도 3은 HCl/에탄올 투여 후, 위염 동물모델에서 적출한 위 조직을 Hematoxylin & Eosin 염색한 조직사진이다. FIG. 1 shows the results of observing mucosal damage and banded bleeding in the gastric region and gastrointestinal tract after administration of HCl / ethanol.
2 is a graph showing the results of measuring the amount of PGE 2 enzyme in a gastritis animal model after administration of HCl / ethanol.
Figure 3 is a tissue picture of Hematoxylin & Eosin stained gastric tissue extracted from gastritis animal model after administration of HCl / ethanol.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다. Hereinafter, examples and the like will be described in detail to help understanding of the present invention. However, the embodiments according to the present invention may be modified in various other forms, and the scope of the present invention should not be interpreted as being limited to the following examples. The embodiments of the present invention are provided to more fully describe the present invention to those skilled in the art.
<실시예 1> 결명자 추출물 제조<Example 1> Preparation of ginseng extract
결명자(Cassia tora L.)를 수세 및 건조한 후 40 mesh로 분쇄한 다음 10배 부피의 정제수를 넣고 3시간 동안 3회 환류추출한 뒤, 얻어진 파우더는 동결건조 하여 물에 녹여 결명자 물 추출물 시료를 얻었다.After washing and drying the Cassia tora L. with 40 mesh and then adding 10 times the volume of purified water and extracting it under reflux for 3 hours, the obtained powder was freeze-dried and dissolved in water to obtain a sample of Cassia tora water extract.
<시험예 1> HCl/에탄올 유도 위염 동물에서 위손상 병변 측정<Test Example 1> Measurement of gastric injury lesions in HCl / ethanol-induced gastritis animals
실험동물은 ㈜ 샘타코바이오코리아(Osan, Korea)로부터 입수한 6주령 암컷 특정병원체 부재(specific-pathogen free) Sprague-Dawley 랫드를 사용하였다. 1주일간의 검역 및 순화를 거친 뒤 건강하다고 판정된 것을 선발하여 시험에 제공하였다. 동물실의 사육환경은 온도 22±3℃,상대습도 50±15%, 환기횟수 10∼15 회/시간, 조명시간 12시간(07:00 점등∼19:00 소등) 및 조도 150∼300 Lux로 설정된 사육환경에서 폴리카보네이트 사육상자(260WX420LX180H mm)에 수용하였으며, 실험동물용 고형사료(Altromin 1314 feed, Lage, Germany)와 상수도수를 자유 급식시켰다. 본 실험에 사용된 모든 동물은 미국 National Research Council(1996)의 "실험동물의 관리와 사용에 관한 지침"에 따라 유지하였으며, 동물실험은 한약진흥재단 동물실험윤리위원회(Institutional Animal Care and Use Committee)의 승인 하에 수행되었다. As the experimental animal, a 6-week-old female specific-pathogen free Sprague-Dawley rat obtained from Samta Co., Ltd. (Osan, Korea) was used. After one week of quarantine and purification, those determined to be healthy were selected and provided to the test. The breeding environment of the animal room is 22 ± 3 ℃ in temperature, 50 ± 15% relative humidity, 10-15 times / hour of ventilation, 12 hours of lighting time (07:00 lights up to 19:00 off), and illuminance 150 to 300 Lux. It was housed in a polycarbonate breeding box (260WX420LX180H mm) in a set breeding environment, and free feed of solid feed for animals (Altromin 1314 feed, Lage, Germany) and tap water. All animals used in this experiment were maintained according to the "National Research Council (1996)" guidelines for the management and use of experimental animals, and the animal experiments were conducted by the Institutional Animal Care and Use Committee. It was carried out with the approval of
시험군의 구성은 정상군(Normal group), 음성 대조군 (Negative Control group), 양성대조군(Positive Control group)으로 오메프라졸(omeprazole, POS, 100 mg/kg) 및 상기 결명자 물 추출물 투여군(100 mg/kg 및 500 mg/kg) 5개 군으로 구성하였다. The test group consisted of a normal group (Normal group), a negative control group (Negative Control group), and a positive control group (omeprazole, POS, 100 mg / kg) as the positive control group, and the administration group of the extractor water extract (100 mg / kg) And 500 mg / kg).
상기 시험군은 24시간 절식시킨 후, 각각의 시료를 단 1회 강제 경구 투여하였으며, 음성 대조군은 증류수를 경구 투여하였다.After the test group was fasted for 24 hours, each sample was forcibly orally administered only once, and the negative control group was orally administered with distilled water.
위염의 유도는 Mizui와 Doteuchi (1983)의 방법에 따라 실험물질을 경구 투여하고 30분 후에 염산-에탄올 용액(140mM 염산+60% 에탄올)을 경구 투여하여 절식, 절수 하에서 1시간 방치 후 에테르(ether)로 치사시켰다. 이 후 위를 적출하여 대만부를 절개하여 위 점막의 손상 정도를 육안으로 관찰하였다. 적출한 위 조직을 핀으로 고정한 다음, 손상된 부위를 광학 디지털 카메라로 촬영하였다. Induction of gastritis was conducted by oral administration of the test substance according to the method of Mizui and Doteuchi (1983), and 30 minutes after oral administration of hydrochloric acid-ethanol solution (140mM hydrochloric acid + 60% ethanol). ). After this, the stomach was removed and the Taiwanese were incised, and the degree of damage to the gastric mucosa was visually observed. The extracted stomach tissue was pinned, and the damaged area was photographed with an optical digital camera.
도 1은 HCl/에탄올 투여 후, 위체부와 위저부의 점막 손상과 띠 모양으로 선상의 출혈을 관찰한 결과를 나타낸 것이다. 여기에서 보듯이, 위의 위염이 유발된 대조군(Control)은 위체부와 위저부에 출혈에 의한 검붉은 선의 출혈흔(hemorrhage)이 발생되어 위 전반적인 부분에 심각한 출혈성 점막손상이 관찰되었다. 반면에 양성대조약물인 오메프라졸(POS) 투여군에서는 HCl/에탄올 대조군에 비해 유의적으로 위손상이 감소되었으며 결명자 물 추출물을 100, 500 ㎎/㎏ 농도로 경구 투여한 약물군은 HCl/에탄올 대조군에 비해 감소되는 경향을 확인할 수 있었다.FIG. 1 shows the results of observing mucosal damage and banded bleeding in the gastric region and gastrointestinal tract after administration of HCl / ethanol. As can be seen here, in the gastritis-induced control (Control), severe hemorrhagic mucosal damage was observed in the entire stomach due to hemorrhage of the dark red line caused by bleeding in the upper and lower parts of the stomach. On the other hand, in the positive control drug omeprazole (POS) -administered group, gastric damage was significantly reduced compared to the HCl / ethanol control group, and the drug group orally administered with a water extract of 100 to 500 mg / kg decreased compared to the HCl / ethanol control group. The tendency to become was confirmed.
<시험예 2> HCl/에탄올 유도 위염 동물모델에서 PGE<Test Example 2> PGE in HCl / ethanol-induced gastritis animal model 22 효소 측정 Enzyme measurement
일반적인 염증반응에는 PGE2 효소가 증가된다고 알려져 있지만 위조직에서는 PGE2 효소가 위산의 억제, 위의 점막 장병 보존, 세포 증식을 촉진하는 역할로 위염이나 위궤양이 발생하게 되면 PGE2 효소가 감소하게 된다. It is known that PGE 2 enzyme is increased in general inflammatory reactions, but in gastric tissue, PGE 2 enzyme decreases PGE 2 enzyme when gastritis or gastric ulcer occurs due to the inhibition of gastric acid, preservation of gastric mucosa, and cell proliferation. .
결명자 물 추출물이 위염 동물모델에서 PGE2 변화시키는지 관찰하기 위해 ELISA방법으로 위조직을 분석하였다. 결명자 물 추출물의 PGE2 분비 효과를 측정하기 위해 PGE2 elisa kit (Enzo, Farmingdale, NY, USA)를 이용하여 실험을 진행하였다. 위조직에서 단백질을 분리하여 제조사에서 제공된 프로토콜에 따라 실험을 진행하였다.Gastric tissue was analyzed by ELISA to observe whether the water extract of the terminator was changed in PGE 2 in gastritis animal model. In order to measure the effect of PGE 2 secretion of the extract of terminator water, an experiment was conducted using a PGE2 elisa kit (Enzo, Farmingdale, NY, USA). Proteins were isolated from gastric tissue and experiments were performed according to the protocol provided by the manufacturer.
(Normal group)Normal
(Normal group)
(Positive Control group)Positive control
(Positive Control group)
(100 mg/kg)Water extract group
(100 mg / kg)
(500 mg/kg)Water extract group
(500 mg / kg)
도 2는 HCl/에탄올 투여 후, 위염 동물모델에서 PGE2 효소 양을 측정한 결과를 나타낸 그래프이다. 그 결과, 정상대조군에서는 42.1± 1.6 ng/㎎, HCl/에탄올 대조군에서는 11.1± 0.2 ng/㎎, 오메프라졸(POS)을 투여한 군에서는 36.9± 3.2 ng/㎎로 대조군에 비하여 역시 유의적인 증가를 나타내었다. 결명자 물 추출물을 100㎎/㎏과 500 ㎎/㎏ 투여한 군에서는 각각 18.2± 0.9 ng/㎎ 및 27± 1 ng/㎎으로 결명자 물 추출물 투여군에서 대조군에 비하여 PGE2가 유의적으로 증가하였다.2 is a graph showing the results of measuring the amount of PGE 2 enzyme in a gastritis animal model after administration of HCl / ethanol. As a result, 42.1 ± 1.6 ng / mg in the normal control group, 11.1 ± 0.2 ng / mg in the HCl / ethanol control group, and 36.9 ± 3.2 ng / mg in the group administered with omeprazole (POS), showing a significant increase compared to the control group. Did. In the group administered with 100 mg / kg and 500 mg / kg of the extractor water extract, PGE 2 was significantly increased in the group administered with the extractor water extract compared to the control group at 18.2 ± 0.9 ng / mg and 27 ± 1 ng / mg, respectively.
<시험예 3> HCl/에탄올 유도 위염 동물모델에서 위조직 형태변화 관찰<Test Example 3> Observation of gastric tissue morphology change in animal model of HCl / ethanol-induced gastritis
위조직을 적출한 뒤 10% NBF에 고정하여, 조직처리 과정을 통해 파라핀으로 포매하였다. 포매가 끝난 조직은 5 ㎛ 두께로 절편을 제작하였으며, Dako Mayer's Hematoxylin (Agilent, Santa clara, California, USA)과 Eosin Y (Sigma, St. Louis, Missouri, USA)를 이용해 염색한 뒤 광학현미경하에 관찰하였다.After the gastric tissue was extracted, it was fixed to 10% NBF and embedded with paraffin through a tissue treatment process. After the embedding, the tissue was fabricated to a thickness of 5 μm, stained with Dako Mayer's Hematoxylin (Agilent, Santa clara, California, USA) and Eosin Y (Sigma, St. Louis, Missouri, USA) and observed under an optical microscope. Did.
Hematoxylin & Eosin 염색법은 검푸른 색을 내는 hematoxylin과 붉은 색을 내는 eosin을 이용하여 동물 조직을 염색하는 방법으로서, 세포핵은 검푸르게 염색되며 대부분의 세포질 성분은 분홍색 또는 붉은색으로 염색되는데, 이 염색법을 이용하여 세포의 핵과 세포질을 관찰할 수 있다.Hematoxylin & Eosin staining is a method of staining animal tissues using dark-colored hematoxylin and red-colored eosin. Cell nuclei are stained darkly, and most cytoplasmic components are stained in pink or red. Thus, the nucleus and cytoplasm of the cell can be observed.
도 3은 HCl/에탄올 투여 후, 위염 동물모델에서 적출한 위 조직을 Hematoxylin & Eosin 염색한 조직사진이다. 여기에서 보듯이, 마우스의 위조직 형태변화를 관찰한 결과, 위염을 유도한 대조군에서 특이적으로 위상피세포의 부풀러짐과 세포간의 경계가 많이 허물어지는 것을 관찰하였다. 양성대조군인 오메프라졸(POS)을 투여한 군에서도 대조군에 비하여 상피세포의 보존이 증가하였다. 결명자 물 추출물을 100 ㎎/㎏과 500 ㎎/㎏ 투여한 군에서는 대조군에 비교하여 억제된 것을 확인할 수 있었다. Figure 3 is a tissue picture of Hematoxylin & Eosin stained gastric tissue extracted from gastritis animal model after administration of HCl / ethanol. As seen here, as a result of observing the morphological changes in the gastric tissue of the mouse, it was observed that in the control group inducing gastritis, the swelling of the epithelial cells and the boundary between the cells were broken down. In the positive control group omeprazole (POS), the preservation of epithelial cells was also increased compared to the control group. In the group administered with 100 mg / kg and 500 mg / kg of the water extract of the terminator, it was confirmed that it was suppressed compared to the control group.
Claims (4)
상기 위장질환이 급성 위염, 만성 위염, 위궤양, 위천공, 및 상기 질환으로 인한 위점막의 미란, 출혈, 발적 및 부종으로부터 선택된 하나 이상인 것을 특징으로 하는 약학적 조성물.According to claim 1,
The gastrointestinal disease is acute gastritis, chronic gastritis, gastric ulcer, gastric perforation, and the pharmaceutical composition, characterized in that at least one selected from erosion, bleeding, redness and edema of the gastric mucosa caused by the disease.
상기 위장질환이 급성 위염, 만성 위염, 위궤양, 위천공, 및 상기 질환으로 인한 위점막의 미란, 출혈, 발적 및 부종으로부터 선택된 하나 이상인 것을 특징으로 하는 식품 조성물.The method of claim 3,
Food composition characterized in that the gastrointestinal disease is at least one selected from acute gastritis, chronic gastritis, gastric ulcer, gastric perforation, and erosion, bleeding, redness and edema of the gastric mucosa caused by the disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180136178A KR102180998B1 (en) | 2018-11-07 | 2018-11-07 | Composition for preventing or treating gastrointestinal disorders comprising extracts of Cassia tora |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180136178A KR102180998B1 (en) | 2018-11-07 | 2018-11-07 | Composition for preventing or treating gastrointestinal disorders comprising extracts of Cassia tora |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200052770A true KR20200052770A (en) | 2020-05-15 |
| KR102180998B1 KR102180998B1 (en) | 2020-11-19 |
Family
ID=70679113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180136178A KR102180998B1 (en) | 2018-11-07 | 2018-11-07 | Composition for preventing or treating gastrointestinal disorders comprising extracts of Cassia tora |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102180998B1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170062563A (en) * | 2015-11-27 | 2017-06-08 | 재단법인 한국한방산업진흥원 | Method of increasing antioxidant and anti-inflammatory activity of Cassiae semen and the fermented extract having increased activity by that |
-
2018
- 2018-11-07 KR KR1020180136178A patent/KR102180998B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170062563A (en) * | 2015-11-27 | 2017-06-08 | 재단법인 한국한방산업진흥원 | Method of increasing antioxidant and anti-inflammatory activity of Cassiae semen and the fermented extract having increased activity by that |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102180998B1 (en) | 2020-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101099004B1 (en) | A composition for preventing or treating a gastrointestinal disease | |
| Deoda et al. | Gastroprotective effect of Rubia cordifolia Linn. on aspirin plus pylorus-ligated ulcer | |
| KR100927101B1 (en) | Composition comprising Acer tegmentosum Maxim. extract or salidroside isolated from the same for preventing or treating gastritis and peptic ulcer | |
| KR101045368B1 (en) | Composition comprising betanin as active ingredient for preventing or treating gastrointestinal disorders | |
| CN108367039B (en) | Composition for treating or preventing liver disease comprising Citrullus spinosa extract as active ingredient | |
| Zaghlool et al. | Comparison between the protective effects of famotidine, ginger and marshmallow on pyloric ligation-induced peptic ulcer in rats | |
| Kakagia et al. | The Use of Pistacia Lentiscus Chia Resin versus Omeprazole in Protecting Male Rats Peptic Mucosa against Cold Restraint Stress | |
| KR102180998B1 (en) | Composition for preventing or treating gastrointestinal disorders comprising extracts of Cassia tora | |
| WO2014133286A1 (en) | Composition containing extracts of artemisia iwayomogi and curcuma longa as active ingredients for preventing, inhibiting, or treating obesity-related diseases | |
| RU2429000C2 (en) | Anti-gastritis and anti-ulcer substance contained in momordicae semen and separated from it momordica saponin | |
| WO2012138076A2 (en) | Composition containing herbal extract mixture for prevention or treatment of gastrointestinal diseases | |
| Hamza et al. | Maha Alkhalf. The prophylactic efficacy of Cardamom (Elettaria cardamomum) extract against aspirin-induced gastric ulcer in a rat model | |
| Christophe et al. | Anti-ulcer and antioxidant activities of the leaf aqueous extract of Corchorus olitorius (Tiliaceae) in rats | |
| EP4081224A1 (en) | Composition for the protection of the gastrointestinal mucosa and for the prevention and treatment of diseases associated therewith | |
| KR101606773B1 (en) | Composition comprising oriental herbal extract for preventing or treating gastrointestinal disorder | |
| WO2021165846A1 (en) | Composition for the protection of the gastrointestinal mucosa and for the prevention and treatment of diseases associated therewith | |
| KR20240003533A (en) | Composition for preventing and treating gastrointerstinal disorders cormprising extracts of Potentilla chinensis | |
| US20110201568A1 (en) | Phyotochemical composition and a process thereof | |
| KR102511606B1 (en) | A composition comprising coptidis rhizoma and evodiae fructus extract for preventing or treating chronic acid reflux esophagitis | |
| KR102453998B1 (en) | Composition for Prevention, Alleviation, or Treatment of Inflammatory Bowel Disease | |
| JP2007063130A (en) | Anti-diabetic composition | |
| AK et al. | Evaluation of anti–ulcer activity of Tinospora cordifolia against experimentally induced gastric ulcers in rats | |
| KR20200127730A (en) | Composition comprising extracts of Houttuynia cordata for acute gastritis and gastric mucosal protection | |
| KR20200127729A (en) | Composition comprising extracts of Chrysanthemu zawadskii for acute gastritis and gastric mucosal protection | |
| KR20200047893A (en) | Composition for prevention and treatment of inflammatory gastrointestinal disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |